# Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

> **NCT03270748** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Trapianto di Midollo Osseo** · enrollment: 78 (actual)

## Conditions studied

- Myeloid Malignancies

## Interventions

- **DRUG:** GvHD prophylaxis

## Key facts

- **NCT ID:** NCT03270748
- **Lead sponsor:** Gruppo Italiano Trapianto di Midollo Osseo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-15
- **Primary completion:** 2022-11-20
- **Final completion:** 2022-11-20
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03270748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03270748, "Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03270748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*